Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis.

Spiering R, Jansen MAA, Wood MJ, Fath AA, Eltherington O, Anderson AE, Pratt AG, van Eden W, Isaacs JD, Broere F, Hilkens CMU.

J Transl Med. 2019 Nov 14;17(1):375. doi: 10.1186/s12967-019-2128-4.

2.

Matured Tolerogenic Dendritic Cells Effectively Inhibit Autoantigen Specific CD4+ T Cells in a Murine Arthritis Model.

Jansen MAA, Spiering R, Ludwig IS, van Eden W, Hilkens CMU, Broere F.

Front Immunol. 2019 Aug 28;10:2068. doi: 10.3389/fimmu.2019.02068. eCollection 2019.

3.

Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.

Ten Brinke A, Martinez-Llordella M, Cools N, Hilkens CMU, van Ham SM, Sawitzki B, Geissler EK, Lombardi G, Trzonkowski P, Martinez-Caceres E.

Front Immunol. 2019 Feb 22;10:181. doi: 10.3389/fimmu.2019.00181. eCollection 2019. Review.

4.

Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients.

Wood MJ, Leckenby A, Reynolds G, Spiering R, Pratt AG, Rankin KS, Isaacs JD, Haniffa MA, Milling S, Hilkens CM.

JCI Insight. 2019 Jan 24;4(2). pii: 125325. doi: 10.1172/jci.insight.125325. [Epub ahead of print]

5.

Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.

Cooles FAH, Anderson AE, Skelton A, Pratt AG, Kurowska-Stolarska MS, McInnes I, Hilkens CMU, Isaacs JD.

Front Immunol. 2018 May 9;9:755. doi: 10.3389/fimmu.2018.00755. eCollection 2018.

6.

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P.

Front Immunol. 2018 Jan 15;8:1844. doi: 10.3389/fimmu.2017.01844. eCollection 2017.

7.

β2 Integrins As Regulators of Dendritic Cell, Monocyte, and Macrophage Function.

Schittenhelm L, Hilkens CM, Morrison VL.

Front Immunol. 2017 Dec 20;8:1866. doi: 10.3389/fimmu.2017.01866. eCollection 2017. Review.

8.

A document-centric approach for developing the tolAPC ontology.

Blfgeh A, Warrender J, Hilkens CMU, Lord P.

J Biomed Semantics. 2017 Nov 28;8(1):54. doi: 10.1186/s13326-017-0159-4.

9.

The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.

Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD.

J Allergy Clin Immunol. 2018 Jan;141(1):445-448.e4. doi: 10.1016/j.jaci.2017.08.026. Epub 2017 Oct 5. No abstract available.

10.

Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?

Jansen MAA, Spiering R, Broere F, van Laar JM, Isaacs JD, van Eden W, Hilkens CMU.

Immunology. 2018 Jan;153(1):51-59. doi: 10.1111/imm.12811. Epub 2017 Sep 18. Review.

11.

T-regulatory cells exhibit a biphasic response to prolonged endurance exercise in humans.

Clifford T, Wood MJ, Stocks P, Howatson G, Stevenson EJ, Hilkens CMU.

Eur J Appl Physiol. 2017 Aug;117(8):1727-1737. doi: 10.1007/s00421-017-3667-0. Epub 2017 Jun 23.

12.

Traceless Cleavage of Protein-Biotin Conjugates under Biologically Compatible Conditions.

Cowell J, Buck M, Essa AH, Clarke R, Vollmer W, Vollmer D, Hilkens CM, Isaacs JD, Hall MJ, Gray J.

Chembiochem. 2017 Sep 5;18(17):1688-1691. doi: 10.1002/cbic.201700214. Epub 2017 Jul 19.

13.

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.

Stojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, Palova-Jelínkova L, Funda DP, Gruden-Movsesijan A, Sofronic-Milosavljevic L, Hilkens CMU, Martinez-Caceres E, Miljkovic D.

Curr Pharm Des. 2017;23(18):2623-2643. doi: 10.2174/1381612823666170214120708. Review.

PMID:
28201972
14.

Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features.

García-González PA, Schinnerling K, Sepúlveda-Gutiérrez A, Maggi J, Hoyos L, Morales RA, Mehdi AM, Nel HJ, Soto L, Pesce B, Molina MC, Cuchacovich M, Larrondo ML, Neira Ó, Catalán DF, Hilkens CM, Thomas R, Verdugo RA, Aguillón JC.

Front Immunol. 2016 Oct 25;7:458. eCollection 2016.

15.

Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1.

Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM.

Clin Exp Immunol. 2017 Jan;187(1):113-123. doi: 10.1111/cei.12870. Epub 2016 Nov 2.

16.

Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T Cells.

Maggi J, Schinnerling K, Pesce B, Hilkens CM, Catalán D, Aguillón JC.

Front Immunol. 2016 Sep 19;7:359. eCollection 2016.

17.

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies.

Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, Ten Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van Kooten C, Lopez Diaz de Cerio A, Nikolic T, Oral HB, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres EM, Hilkens CMU.

PeerJ. 2016 Aug 30;4:e2300. doi: 10.7717/peerj.2300. eCollection 2016.

18.

Reduced TCR-dependent activation through citrullination of a T-cell epitope enhances Th17 development by disruption of the STAT3/5 balance.

Tibbitt C, Falconer J, Stoop J, van Eden W, Robinson JH, Hilkens CM.

Eur J Immunol. 2016 Jul;46(7):1633-43. doi: 10.1002/eji.201546217.

19.

Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.

Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl E, Dunn J, Dickinson AM, Hilkens CM, Isaacs JD.

Ann Rheum Dis. 2017 Jan;76(1):227-234. doi: 10.1136/annrheumdis-2015-208456. Epub 2016 Apr 26.

20.

AIRE is not essential for the induction of human tolerogenic dendritic cells.

Crossland KL, Abinun M, Arkwright PD, Cheetham TD, Pearce SH, Hilkens CM, Lilic D.

Autoimmunity. 2016 Jun;49(4):211-8. doi: 10.3109/08916934.2016.1148692. Epub 2016 Feb 25.

PMID:
26912174
21.

Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort.

Ten Brinke A, Hilkens CM, Cools N, Geissler EK, Hutchinson JA, Lombardi G, Lord P, Sawitzki B, Trzonkowski P, Van Ham SM, Martinez-Caceres EM.

Mediators Inflamm. 2015;2015:471719. doi: 10.1155/2015/471719. Epub 2015 Dec 24. Review.

22.

Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis.

Reynolds G, Gibbon JR, Pratt AG, Wood MJ, Coady D, Raftery G, Lorenzi AR, Gray A, Filer A, Buckley CD, Haniffa MA, Isaacs JD, Hilkens CM.

Ann Rheum Dis. 2016 May;75(5):899-907. doi: 10.1136/annrheumdis-2014-206578. Epub 2015 Apr 28.

23.

Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2.

Maney NJ, Reynolds G, Krippner-Heidenreich A, Hilkens CMU.

J Immunol. 2014 Nov 15;193(10):4914-4923. doi: 10.4049/jimmunol.1302929. Epub 2014 Oct 6.

24.

A negative feedback loop mediated by STAT3 limits human Th17 responses.

Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CM.

J Immunol. 2014 Aug 1;193(3):1142-50. doi: 10.4049/jimmunol.1302467. Epub 2014 Jun 27.

25.

Emerging immunotherapies for rheumatoid arthritis.

Reynolds G, Cooles FA, Isaacs JD, Hilkens CM.

Hum Vaccin Immunother. 2014;10(4):822-37. Epub 2014 Feb 17. Review.

26.

IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses.

Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, Ho AW, See P, Shin A, Wasan PS, Hoeffel G, Malleret B, Heiseke A, Chew S, Jardine L, Purvis HA, Hilkens CM, Tam J, Poidinger M, Stanley ER, Krug AB, Renia L, Sivasankar B, Ng LG, Collin M, Ricciardi-Castagnoli P, Honda K, Haniffa M, Ginhoux F.

Immunity. 2013 May 23;38(5):970-83. doi: 10.1016/j.immuni.2013.04.011.

27.

Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Hilkens CM, Isaacs JD.

Clin Exp Immunol. 2013 May;172(2):148-57. doi: 10.1111/cei.12038. Review.

28.

The choice of adjuvant determines the cytokine profile of T cells in proteoglycan-induced arthritis but does not influence disease severity.

Stoop JN, Tibbitt CA, van Eden W, Robinson JH, Hilkens CM.

Immunology. 2013 Jan;138(1):68-75. doi: 10.1111/imm.12019.

29.

Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study.

Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, Parker C, Dunn M, Catt M, Jagger C, von Zglinicki T, Kirkwood TB.

Mech Ageing Dev. 2012 Jun;133(6):456-66. doi: 10.1016/j.mad.2012.05.005. Epub 2012 Jun 1.

PMID:
22663935
30.

A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease.

Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, Isaacs JD.

Ann Rheum Dis. 2012 Aug;71(8):1374-81. doi: 10.1136/annrheumdis-2011-200968. Epub 2012 Apr 24.

31.

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD.

Rheumatology (Oxford). 2012 Aug;51(8):1397-406. doi: 10.1093/rheumatology/kes038. Epub 2012 Mar 24.

PMID:
22447884
32.

Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?

Stoop JN, Robinson JH, Hilkens CM.

Ann Rheum Dis. 2011 Sep;70(9):1526-33. doi: 10.1136/ard.2011.151654. Review.

PMID:
21804099
33.

Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease.

Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CM, Fisher AJ, Corris PA, Lordan JL, Ward C.

Eur Respir J. 2011 Jun;37(6):1378-85. doi: 10.1183/09031936.00067110. Epub 2010 Nov 25.

34.

Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses.

Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM.

Arthritis Rheum. 2010 Dec;62(12):3656-65. doi: 10.1002/art.27756.

35.

Low-strength T-cell activation promotes Th17 responses.

Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CM.

Blood. 2010 Dec 2;116(23):4829-37. doi: 10.1182/blood-2010-03-272153. Epub 2010 Aug 16.

36.

Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

Harry RA, Anderson AE, Isaacs JD, Hilkens CM.

Ann Rheum Dis. 2010 Nov;69(11):2042-50. doi: 10.1136/ard.2009.126383. Epub 2010 Jun 15.

37.

Development of dendritic cell-based immunotherapy for autoimmunity.

Hilkens CM, Isaacs JD, Thomson AW.

Int Rev Immunol. 2010 Apr;29(2):156-83. doi: 10.3109/08830180903281193. Review.

PMID:
20199240
38.

Airway epithelial cells as guardians of immune homeostasis?

Brodlie M, Eger K, Hilkens CM, Ward C.

Thorax. 2009 Nov;64(11):1009. doi: 10.1136/thx.2009.120121. No abstract available.

PMID:
19864551
39.

Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.

Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM.

Ann Rheum Dis. 2010 Jun;69(6):1200-7. doi: 10.1136/ard.2009.110502. Epub 2009 Sep 22.

PMID:
19773288
40.

Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.

Wang XN, Haniffa MA, Holtick U, Collin MP, Jackson G, Hilkens CM, Holler E, Edinger M, Hoffmann P, Dickinson AM.

Transplantation. 2009 Jul 27;88(2):188-97. doi: 10.1097/TP.0b013e3181ac14ce.

PMID:
19623013
41.

A novel paradigm for dendritic cells as effectors of cartilage destruction.

Lakey RL, Morgan TG, Rowan AD, Isaacs JD, Cawston TE, Hilkens CM.

Rheumatology (Oxford). 2009 May;48(5):502-7. doi: 10.1093/rheumatology/kep040. Epub 2009 Mar 5.

PMID:
19269957
42.

Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells.

Ward C, Eger K, Diboll J, Jones D, Haniffa MA, Brodlie M, Fisher A, Lordan JL, Corris PA, Hilkens CM.

Thorax. 2009 May;64(5):430-5. doi: 10.1136/thx.2008.104067. Epub 2009 Jan 21.

43.

LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells.

Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM.

J Leukoc Biol. 2009 Feb;85(2):243-50. doi: 10.1189/jlb.0608374. Epub 2008 Nov 6.

44.

Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells.

Anderson AE, Sayers BL, Haniffa MA, Swan DJ, Diboll J, Wang XN, Isaacs JD, Hilkens CM.

J Leukoc Biol. 2008 Jul;84(1):124-33. doi: 10.1189/jlb.1107744. Epub 2008 Apr 22.

45.

Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells.

Holtick U, Marshall SR, Wang XN, Hilkens CM, Dickinson AM.

Transplantation. 2008 Mar 15;85(5):757-66. doi: 10.1097/TP.0b013e31816650f6.

PMID:
18337671
46.

Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells.

Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP.

J Immunol. 2007 Aug 1;179(3):1595-604.

47.

Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice.

von Delwig A, Hilkens CM, Altmann DM, Holmdahl R, Isaacs JD, Harding CV, Robertson H, McKie N, Robinson JH.

Arthritis Res Ther. 2006;8(4):R93.

48.

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P.

Cancer Res. 2004 Sep 1;64(17):5934-7.

49.

Sustained IL-12 signaling is required for Th1 development.

Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM.

J Immunol. 2004 Jan 1;172(1):61-9.

50.

Differential responses to IFN-alpha subtypes in human T cells and dendritic cells.

Hilkens CM, Schlaak JF, Kerr IM.

J Immunol. 2003 Nov 15;171(10):5255-63.

Supplemental Content

Loading ...
Support Center